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Abstract  
The occurrence of epithelial desquamation, erythema, and erosions on the gingival 
tissue could be described in literature as “desquamative gingivitis” (DG), mostly due 
to a wide range of autoimmune/dermatological disorders. The objective of this 
systematic review was to assess the efficiency of the different treatments for DG.  
The research was conducted on the following databases: PubMed, Google Scholar, 
NIH (National Institute of Health), Up to Date, Scopus, Cochrane Library, Web of 
Science. The P.I.C.O. question was as follows: human patients with clinical-
pathological diagnosis of DG (Patients); any topic, systemic medication, 
photobiomodulation or periodontal treatments (Intervention); no treatment, placebo or 
other drug (Comparison); and effectiveness in terms of improvement of symptoms 
(primary Outcome) and signs (secondary Outcome). The PROSPERO record is 
number CRD42018084531. 
A total of 2174 potential results were acquired from the various databases, of which 
998 were duplicates; the remaining 1176 studies were submitted to a first reading of 
title and abstract: 1137 articles had to be excluded, with 994 being not inherent to the 
purposes of this review, and 143 being published in languages other than English. The 
remaining 39 articles were subjected to full reading; 4 Randomized Controlled Trials 
were considered eligible but only 2 finally analysed. 
To date, 0.05% clobetasol propionate ointment compared with placebo, in the 
management of signs and symptoms of DG, showed no statistically significant 
differences. Differently, a structured plaque control appeared to be successful in 
reducing plaque and improving signs and related pain, with statistically significant 
differences regarding related symptoms, plaque index and mucosal disease score.  
Clinical relevance Based on our results, it is actually not possible to draw certain and 
positive conclusions as to the best management modalities for DG. Future research 
should be conducted in order to establish a proper therapy for this condition, primarily 
considering that it is mainly a characteristic clinical representation of dissimilar 
autoimmune bullous diseases. A promising field could be that of periodontal therapy 
but more data are however needed. 
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To the Editor,  
 Desquamative gingivitis (DG) is a characteristic clinical representation of many 
autoimmune diseases, such as oral lichen planus (OLP), mucous membrane 
pemphigoid (MMP), pemphigus vulgaris (PV), bullous pemphigoid, erythema 
multiforme, linear IgA disease, systemic lupus erythematosus, epidermolysis bullosa, 
and dermatitis herpetiformis. It can also arise as consequence of hypersensitivity 
reaction to some antigens contained in toothpastes, mouthrinses, chewing gum or 
foods, and less frequently in patients with plasma cell gingivitis, chronic ulcerative 
stomatitis and orofacial granulomatosis (1, 2). 
DG usually presents with erythema, shedding and ulceration of both free and attached 
gingiva (mainly vestibular), and, differently from plaque-induced inflammation, it 
could extend beyond the marginal border, involving the full width of the gums and 
often the alveolar mucosa (3, 4). 
To date, there are no generally established guidelines for the treatment of DG (1-4). 
Treatment should be undertaken with the goal of achieving control of symptoms with 
minimum side effects (1). In the last decade some evidence suggested that DG could 
play a role in increasing the long-term risk for periodontal tissue breakdown (5), 
detailing moreover that an inappropriate home oral hygiene could worsen the gingival 
status in DG patients, if compared to controls (6). For these reasons, some Authors 
have decided to start periodontal therapies for patients with DG (7).  
Consequently, with such dissimilar conclusions at hand, we sought to systematically 
review therapies for DG to incorporate research in order to provide a base for the 
elaboration of more consistent and effective management approaches.  
MATERIALS AND METHODS 
From December 2016 to December 2017, two researchers (MC and PGA) carried out 
research on the treatment of DG.  
The P.I.C.O. (Patient, Intervention, Control, Outcome) question [based on the 
Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA)] for 
this investigation was: “In populations with DG, which intervention is effective in 
improving pain and/or relieving related symptoms compared to other intervention or 
placebo?” 
The P.I.C.O. question was then developed as follows: human patients with clinical 
diagnosis of DG (Patients) related to any possible cause; any topic, systemic 
medication, photobiomodulation or periodontal treatments (Intervention); no 
treatment, placebo or other drug (Comparison); and effectiveness in terms of 
improvement of symptoms (primary Outcome) and clinical signs (secondary 
Outcome). 
Inclusion criteria were: randomized and controlled clinical trials conducted on human 
beings affected by DG, treated by dentist / odontostomatologist, in the presence of a 
comparison group, under placebo or proper medications. 
Exclusion criteria were: case reports, case series, reviews, open clinical trials, 
prospective or retrospective studies, letters to editors concerning DG therapy, as well 
as studies published in non-English language, and "non-inherent" studies, defined as 
such when: 
- Not performed on humans; 
- DG was not mentioned in any way; 
- DG was simply cited as one of the many clinical manifestations observed in patients, 
without further specification; 
- DG was documented and treated together with other atrophic-erosive oral lesions, 
without offering any distinctive data on the efficacy and/or tolerability of a given 
therapeutic protocol in the management of DG alone. 
The PROSPERO record is number CRD42018084531. 
 
   Search Strategy 
The research was conducted on the following databases: PubMed, Google Scholar, 
NIH (National Institute of Health), Up to Date, Scopus, Cochrane Library, Web of 
Science. Initially, there were no restrictions regarding the language, with not-in-
English studies excluded in the first phase of study selection.  
Conversely, no restriction regarding the publishing year was applied whatsoever.  
 
   Study selection and data extraction 
References were exported into the EndNote® program (Thomson Reuters). Two 
reviewers (PGA and MC), independently from one another, proceeded to classify the 
various results. Any disagreements were resolved by consulting other reviewers (RB 
and AG) until a consensus was reached. 
After excluding not-inherent and not-in-English studies, based on the reading of titles 
and abstracts, full text of the remaining articles was acquired and read; later, their 
classification was carried out, based on the eligibility criteria mentioned above.  
 
Quality assessment 
The reviewers (PGA and MC) proceeded to assess the quality of the studies included 
through the PEDro scale, applied in previous systematic reviews, up to the current 
year. 
This scale considers the following parameters: random allocation, concealed 
allocation, similarity between the groups at baseline, subject, therapist and assessors 
blinding, less than 15% dropouts, intention-to-treat analysis, statistical comparisons 
between the groups, point measures and variability data.  
According to this scale, controlled clinical trial can be considered of good quality if 
PEDro score is ≥6 with a maximum score of 10. 
 
   Data synthesis 
Through the compilation of the Excel sheet, information was extracted from each of 
the selected studies regarding study design, main characteristics of the selected 
sample (country of origin, size, distribution by gender and age), type of therapeutic 
protocol, duration of the intervention and results. 
In the light of the limited number of RCTs and the high degree of diversification 
regarding both methods and therapies, a meta-analysis could not be performed: 
therefore, a narrative description of the results has been presented in this current 
review. 
 
RESULTS 
A total of 2174 potential results were acquired from the various databases, of which 
998 were duplicates.                
The remaining 1176 studies were submitted to a first reading of title and abstract: 
1137 articles had to be excluded, with 994 being not inherent to the purposes of this 
review, and 143 being published in languages other than English.  
The remaining 39 articles were subjected to full reading: 2 Randomized Controlled 
Trials were considered eligible for this review (12, 16).  
On the other hand, 11 case reports, 7 case-series, 6 pilot studies, 5 reviews, 4 open 
clinical trials, 2 not-inherent RCT, 1 retrospective study and 1 letter to Publisher were 
also excluded (Figure 1).  
Table I summarizes the main characteristics of the two included trials. 
 
Quality assessment 
The quality assessment using the PEDro scale revealed values ranging from 6 to 10 
with the scale ranging from 0 to 10. The grade 6 of the study conducted by Stone and 
co-workers was due to the absence of a blinding approach (Table II). 
 
 General characteristics of the sample 
The size of the trial samples varies from 22 to 82, with an age-range between 25 and 
78 years, and an approximate female to male ratio of 6:1. 
In 2009, Motta and co-workers (16) carried out an 8-week double-blind, crossover, 
placebo-controlled clinical trial in 22 Brazilian patients, divided in two groups in 
order to compare the efficacy of 0.05% clobetasol propionate ointment with placebo 
(hydroxyethyl cellulose) in the management of signs and symptoms of DG, showing 
no statistically significant differences (p>0.05). Group 1 was a sample of five PV 
female patients, treated systemically with prednisone and/or azathioprine in the 
previous six months, whereas group 2 consisted of nine patients with OLP, five with 
MMP and three with PV, thus consisting of a total of 17 patients. 
Later, in 2015, Stone and co-workers (12) conducted a 20-week randomized 
controlled trial on 82 British patients affected by OLP-related DG, in order to 
determine the clinical efficacy of structured plaque control, provided to 43 patients, 
through the addition of a powered toothbrush and inter-dental cleaning aids TePe® 
extra soft inter-dental brushes (TePe Munhygienprodukter, Malmo, Sweden) ranging 
from ISO size 1–6 or Oral-B dental floss (Procter & Gamble, Weybridge, UK). Such 
addition, when compared to the normal plaque control regimen maintained by the 39 
control cases, appeared to be successful in reducing plaque and improving signs and 
symptoms of DG, with statistically significant differences regarding related 
symptoms, plaque index and mucosal disease score.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
The aim of this systematic review was to investigate the current state of the art 
regarding the therapy of DG. Based on these current results, it is actually not possible 
to draw certain and encouraging conclusions as to the best management modalities. 
Corrocher and co-workers’ RCT (8) was excluded due to the questionable eligibility 
criteria provided as well as Stone and co-workers’ RCT (9), due to the incompatibility 
of its outcomes with the P.I.C.O. question of the present review. 
On the other hand, the double-blind, crossover, placebo-controlled trial published by 
Motta and co-workers (10), assessing the efficacy of topical clobetasol propionate on 
DG patients, met our criteria of inclusion, showing a slight, not-significant 
improvement of clinical signs and symptoms between topical steroid and placebo. On 
the other hand, Stone and co-workers (11) reported a statistically significant 
improvement through a structured plaque control both in plaque control and oro-
mucosal disease (p<0.001 for Plaque Index and Escudier index), with no statistically 
significant changes regarding perception of pain (p>0.05 for OHIP and VAS).  
The present systematic review reveals a substantial lack in current understanding of 
the pathogenesis and risk factors of DG. Hence, further clinical trials in large samples 
of patients are required to establish at first if clobetasol propionate is just as unreliable 
as showed by Motta et al. not only on patients with OLP-related DG, but also 
PV/PMM-related DG, where DG tends to persist, despite the healing of the cutaneous 
and oral signs. 
On the other hand, to assess the role of periodontal therapy in the management of DG, 
although our group provided evidence of microbiologic alterations in subgingival 
plaque between autoimmune and plaque-induced gingivitis (12), further and wider 
randomized prospective studies are needed to investigate this fascinating association. 
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Table I.  Characteristics of RCT examining treatment on patients with Desquamative Gingivitis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Authors, year Country Oral disease Sample Groups under comparison Duration Drug/dose 
Motta et al. 
2009 Brazil 
PV, MMP, 
OLP 22 (17 F) 5 vs 17 8 wks 
0,05% propionate clobetasol ointment Vs 
hydroxylhetyl cellulose 
Stone et al. 
2015 UK OLP 
82 data from 79 
patients 39 vs 43 20 wks 
Powered toothbrush/interdental cleaning 
aids Vs normal plaque control 
Table II. Quality assessment PEDro scale 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Authors, 
year 
1 2 3 4 5 6 7 8 9 10 11 Total 
Motta et al. 
2009 
Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes 9 of 10 
Stone et al. 
2015 
Yes Yes No Yes No No No Yes Yes Yes Yes 6 of 10 
FIGURE 1. Flow-chart of systematic review synthesis 
 
 
 
 
 
 
 
 
 
 
